التفاصيل البيبلوغرافية
العنوان: |
Optimizing Central Nervous System Drug Development Using Molecular Imaging. |
المؤلفون: |
Hargreaves, RJ, Hoppin, J, Sevigny, J, Patel, S, Chiao, P, Klimas, M, Verma, A |
المصدر: |
Clinical Pharmacology & Therapeutics; Jul2015, Vol. 98 Issue 1, p47-60, 14p |
مصطلحات موضوعية: |
CENTRAL nervous system diseases, THERAPEUTICS, IMAGING systems, DRUG development, BIOMARKERS |
مستخلص: |
Advances in multimodality fusion imaging technologies promise to accelerate the understanding of the systems biology of disease and help in the development of new therapeutics. The use of molecular imaging biomarkers has been proven to shorten cycle times for central nervous system (CNS) drug development and thereby increase the efficiency and return on investment from research. Imaging biomarkers can be used to help select the molecules, doses, and patients most likely to test therapeutic hypotheses by stopping those that have little chance of success and accelerating those with potential to achieve beneficial clinical outcomes. CNS imaging biomarkers have the potential to drive new medical care practices for patients in the latent phases of progressive neurodegenerative disorders by enabling the detection, preventative treatment, and tracking of disease in a paradigm shift from today's approaches that have to see the overt symptoms of disease before treating it. [ABSTRACT FROM AUTHOR] |
|
Copyright of Clinical Pharmacology & Therapeutics is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
قاعدة البيانات: |
Complementary Index |